A field efficacy trial of a trivalent vaccine containing porcine circovirus type 2a and 2b, and Mycoplasma hyopneumoniae in three herds

Abstract

Background: This field trial was designed to evaluate the efficacy of a new trivalent vaccine containing porcine circovirus type 2a and 2b (PCV2a/b), and Mycoplasma hyopneumoniae at three independent locations. Methods: Three farms were selected based on their history of PCV2 and M. hyopneumoniae co-infection. Each farm housed a total of 60, 3-day-old pigs that were randomly allocated to one of three treatment groups. Pigs were administered the trivalent vaccine intramuscularly with either a 1.0 ml dose at 3 and 24 days of age or a 2.0 ml dose at 21 days of age in accordance with the manufacturer's recommendations.Results: Clinically, the average daily weight gain of the one-dose and two-dose vaccinated groups within all three farms was significantly higher (p < 0.05) than those of unvaccinated animals during the growing (70-112 days of age), finishing (112-175 days of age) and overall (3-175 days of age) stages of production. One-dose and twodose vaccinated animals elicited neutralizing antibodies and interferon-γ-secreting cells (IFN-γ-SC), which reduced the amount of PCV2 in terms of blood load and reduced the severity of lymphoid lesions when compared with unvaccinated animals. Similarly, one-dose and two-dose vaccinated animals elicited IFN-γ-SC, which reduced the amount of M. hyopneumoniae in terms of laryngeal load and reduced the severity of lung lesions. Conclusions:The intramuscular administration of either one or two doses of trivalent vaccine was not significantly different in any of the evaluated parameters. The results of field trial demonstrated that the trivalent vaccine was efficacious in the protection of swine herds where PCV2d and M. hyopneumoniae were in active circulation.

A Field Efficacy Trial of Recombinant Porcine Circovirus Type 2d Vaccine in Three Herds

“…Some authors have stated that it is preferable to establish the sow’s infection or vaccination history before vaccinating piglets at 3–4 weeks of age, as MDAs may interfere with the formation of vaccine-specific antibodies and reduce vaccine efficacy [ 21 , 22 , 23 , 24 ]. However, in our study, both IgG and NA antibodies increased in the experimental animals after vaccination, indicating that MDAs had no effect on vaccine efficacy, in agreement with what was reported by Um et al [ 25 ] and Kim and Hanh [ 26 ].…”

Detection of Porcine Circovirus 1/2/3 and Genetic Analysis of Porcine Circovirus 2 in Wild Boar from Jiangxi Province of China

“…Three main aspects make up the huge PCV2 flood. First, failure to vaccinate pigs with PCV2 leads to immune response suppression, which lowers overall production efficiency [ 18 ]. Second, it is extremely expensive to control and prevent PCV2 infection [ 19 ].…”

Revisiting Porcine Circovirus Infection: Recent Insights and Its Significance in the Piggery Sector

“…However, later studies have found that vaccination against M. hyopneumoniae alone did not reduce PCV2-induced lesions [ 315 ]. Recently, bivalent (containing PCV2b and M. hyopneumoniae ) and trivalent vaccines (containing PCV2a/b and M. hyopneumoniae ) under experimental conditions were tested against dual infections (PCV2d and M. hyopneumoniae ), which successfully elicited effective protective immunity against concerned pathogens in the form of PCV2-specific neutralizing antibodies and PCV2- and M. hyopneumoniae -specific IFN-γ-SC [ 316 , 317 , 318 ]. Furthermore, trivalent vaccine mixture (3FLEX) was shown to be efficacious against a triple challenge of M. hyopneumoniae , PCV2, and PRRSV in pigs [ 319 ].…”